A study using prostate cancer cells with the P223L and V274F mutations (DU145 prostate cancer cells) and cells with the R273H and Q331R mutations (CWRR1 cells, derived from CWR22 castration-resistant prostate cancer cells) demonstrated through immunoprecipitation with Pab240 followed by immunoblotting with anti-p53 that there was less p53 in the unfolded fraction after treating native cell lysates with ReACp53 [63]. The gene discussed is TP53; the disease is prostate carcinoma.